Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using...

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• The epidermal growth factor receptor (EGFR) signaling pathway is crucial in non-small cell lung carcinoma (NSCLC) development.
• Activating mutations in EGFR kinase domain are common in tumors responsive to EGFR kinase inhibitors.
• There is a need for biomarkers and imaging to identify patients benefiting from targeted EGFR therapies.

Purpose of the Study:

• To develop a novel radiotracer for molecular imaging of EGFR mutations in NSCLC.
• To assess the efficacy of [(18)F]F-PEG6-IPQA in discriminating NSCLC xenografts with specific EGFR mutations.

Main Methods:

• Synthesis of 4-[(3-iodophenyl)amino]-7-{2-[2-{2-(2-[2-{2-([(18)F]fluoroethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}-ethoxy]-quinazoline-6-yl-acrylamide ([(18)F]F-PEG6-IPQA), a novel radiotracer.
• Positron Emission Tomography (PET) imaging in tumor-bearing mice with different EGFR mutation statuses.
• Evaluation of tracer binding selectivity and affinity to mutant EGFR.

Main Results:

• [(18)F]F-PEG6-IPQA demonstrated selective and irreversible binding to the active mutant L858R EGFR kinase.
• PET imaging successfully discriminated NSCLC xenografts with L858R mutant EGFR from those with wild-type EGFR or dual L858R/T790M mutations.
• The T790M mutation was found to prevent irreversible binding of the radiotracer.

Conclusions:

• [(18)F]F-PEG6-IPQA shows promise as a PET imaging agent for identifying specific EGFR mutations in NSCLC.
• This radiotracer could facilitate patient selection for targeted therapies, including EGFR kinase inhibitors like gefitinib and erlotinib.
• The ability to differentiate EGFR mutation types may improve personalized treatment strategies for NSCLC.